Page last updated: 2024-08-21

indazoles and arry-614

indazoles has been researched along with arry-614 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bohannan, Z; Cable, L; Calvo, MC; Garcia-Manero, G; Hogeland, G; Jabbour, E; Kantarjian, H; Khoury, HJ; Komrokji, R; Lancet, J; List, A; Maloney, L; Ptaszynski, M; Rush, S; Winski, SL	1
Bohannan, ZS; Gañán-Gómez, I; Garcia-Manero, G	1
Assal, A; Bachegowda, L; Bartenstein, M; Bhagat, T; Bhattacharyya, S; Boultwood, J; Brown, S; Burgess, LE; Chantry, D; Garrus, J; Giricz, O; Gordon-Mitchell, S; Gross, S; Guha, C; Hogeland, G; Mantzaris, I; Morrone, K; Munson, M; Nwankwo, G; Pellagatti, A; Platanias, L; Pradhan, K; Ramachandra, N; Rizzi, J; Rodriguez, M; Schinke, C; Shahnaz, S; Shastri, A; Steidl, U; Sukrithan, V; Verma, A; Winski, SL; Wollenberg, L; Wright, D; Yu, Y; Zou, Y	1

Trials

1 trial(s) available for indazoles and arry-614

Article	Year
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Mar-01, Volume: 21, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Female; Humans; Indazoles; Male; Middle Aged; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Receptor, TIE-2; Treatment Outcome; Urea	2015

Article

Year

A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Mar-01, Volume: 21, Issue:5

Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Female; Humans; Indazoles; Male; Middle Aged; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Receptor, TIE-2; Treatment Outcome; Urea

2015

Other Studies

2 other study(ies) available for indazoles and arry-614

Article	Year
p38 MAPK in MDS. Aging, 2015, Volume: 7, Issue:6 Topics: Gene Expression Regulation; Humans; Indazoles; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Urea	2015
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancer research, 2016, 08-15, Volume: 76, Issue:16 Topics: Angiopoietin-1; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Gene Knockdown Techniques; Humans; Indazoles; Leukemia, Myeloid, Acute; Male; Mice; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Proportional Hazards Models; Receptor, TIE-2; Urea	2016

Article

Year

p38 MAPK in MDS.

Aging, 2015, Volume: 7, Issue:6

Topics: Gene Expression Regulation; Humans; Indazoles; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Urea

2015

Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Cancer research, 2016, 08-15, Volume: 76, Issue:16

Topics: Angiopoietin-1; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Gene Knockdown Techniques; Humans; Indazoles; Leukemia, Myeloid, Acute; Male; Mice; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Proportional Hazards Models; Receptor, TIE-2; Urea

2016